Cargando…

HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020

In response to increasing pretreatment drug resistance (PDR), Mexico changed its national antiretroviral treatment (ART) policy, recommending and procuring second-generation integrase strand-transfer inhibitor (INSTI)-based regimens as preferred first-line options since 2019. We present a four-year...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Morales, Claudia, Tapia-Trejo, Daniela, Matías-Florentino, Margarita, Quiroz-Morales, Verónica Sonia, Dávila-Conn, Vanessa, Beristain-Barreda, Ángeles, Cárdenas-Sandoval, Miroslava, Becerril-Rodríguez, Manuel, Iracheta-Hernández, Patricia, Macías-González, Israel, García-Mendiola, Rebecca, Guzmán-Carmona, Alejandro, Zarza-Sánchez, Eduardo, Cruz, Raúl Adrián, González-Rodríguez, Andrea, Reyes-Terán, Gustavo, Ávila-Ríos, Santiago
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708254/
https://www.ncbi.nlm.nih.gov/pubmed/34959542
http://dx.doi.org/10.3390/pathogens10121587
_version_ 1784622638202617856
author García-Morales, Claudia
Tapia-Trejo, Daniela
Matías-Florentino, Margarita
Quiroz-Morales, Verónica Sonia
Dávila-Conn, Vanessa
Beristain-Barreda, Ángeles
Cárdenas-Sandoval, Miroslava
Becerril-Rodríguez, Manuel
Iracheta-Hernández, Patricia
Macías-González, Israel
García-Mendiola, Rebecca
Guzmán-Carmona, Alejandro
Zarza-Sánchez, Eduardo
Cruz, Raúl Adrián
González-Rodríguez, Andrea
Reyes-Terán, Gustavo
Ávila-Ríos, Santiago
author_facet García-Morales, Claudia
Tapia-Trejo, Daniela
Matías-Florentino, Margarita
Quiroz-Morales, Verónica Sonia
Dávila-Conn, Vanessa
Beristain-Barreda, Ángeles
Cárdenas-Sandoval, Miroslava
Becerril-Rodríguez, Manuel
Iracheta-Hernández, Patricia
Macías-González, Israel
García-Mendiola, Rebecca
Guzmán-Carmona, Alejandro
Zarza-Sánchez, Eduardo
Cruz, Raúl Adrián
González-Rodríguez, Andrea
Reyes-Terán, Gustavo
Ávila-Ríos, Santiago
author_sort García-Morales, Claudia
collection PubMed
description In response to increasing pretreatment drug resistance (PDR), Mexico changed its national antiretroviral treatment (ART) policy, recommending and procuring second-generation integrase strand-transfer inhibitor (INSTI)-based regimens as preferred first-line options since 2019. We present a four-year observational study describing PDR trends across 2017–2020 at the largest HIV diagnosis and primary care center in Mexico City. A total of 6688 baseline protease-reverse transcriptase and 6709 integrase sequences were included. PDR to any drug class was 14.4% (95% CI, 13.6–15.3%). A significant increasing trend for efavirenz/nevirapine PDR was observed (10.3 to 13.6%, p = 0.02). No increase in PDR to second-generation INSTI was observed, remaining under 0.3% across the study period. PDR was strongly associated with prior exposure to ART (aOR: 2.9, 95% CI: 1.9–4.6, p < 0.0001). MSM had higher odds of PDR to efavirenz/nevirapine (aOR: 2.0, 95% CI: 1.0–3.7, p = 0.04), reflecting ongoing transmission of mutations such as K103NS and E138A. ART restarters showed higher representation of cisgender women and injectable drug users, higher age, and lower education level. PDR to dolutegravir/bictegravir remained low in Mexico City, although further surveillance is warranted given the short time of ART optimization. Our study identifies demographic characteristics of groups with higher risk of PDR and lost to follow-up, which may be useful to design differentiated interventions locally.
format Online
Article
Text
id pubmed-8708254
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87082542021-12-25 HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020 García-Morales, Claudia Tapia-Trejo, Daniela Matías-Florentino, Margarita Quiroz-Morales, Verónica Sonia Dávila-Conn, Vanessa Beristain-Barreda, Ángeles Cárdenas-Sandoval, Miroslava Becerril-Rodríguez, Manuel Iracheta-Hernández, Patricia Macías-González, Israel García-Mendiola, Rebecca Guzmán-Carmona, Alejandro Zarza-Sánchez, Eduardo Cruz, Raúl Adrián González-Rodríguez, Andrea Reyes-Terán, Gustavo Ávila-Ríos, Santiago Pathogens Article In response to increasing pretreatment drug resistance (PDR), Mexico changed its national antiretroviral treatment (ART) policy, recommending and procuring second-generation integrase strand-transfer inhibitor (INSTI)-based regimens as preferred first-line options since 2019. We present a four-year observational study describing PDR trends across 2017–2020 at the largest HIV diagnosis and primary care center in Mexico City. A total of 6688 baseline protease-reverse transcriptase and 6709 integrase sequences were included. PDR to any drug class was 14.4% (95% CI, 13.6–15.3%). A significant increasing trend for efavirenz/nevirapine PDR was observed (10.3 to 13.6%, p = 0.02). No increase in PDR to second-generation INSTI was observed, remaining under 0.3% across the study period. PDR was strongly associated with prior exposure to ART (aOR: 2.9, 95% CI: 1.9–4.6, p < 0.0001). MSM had higher odds of PDR to efavirenz/nevirapine (aOR: 2.0, 95% CI: 1.0–3.7, p = 0.04), reflecting ongoing transmission of mutations such as K103NS and E138A. ART restarters showed higher representation of cisgender women and injectable drug users, higher age, and lower education level. PDR to dolutegravir/bictegravir remained low in Mexico City, although further surveillance is warranted given the short time of ART optimization. Our study identifies demographic characteristics of groups with higher risk of PDR and lost to follow-up, which may be useful to design differentiated interventions locally. MDPI 2021-12-08 /pmc/articles/PMC8708254/ /pubmed/34959542 http://dx.doi.org/10.3390/pathogens10121587 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
García-Morales, Claudia
Tapia-Trejo, Daniela
Matías-Florentino, Margarita
Quiroz-Morales, Verónica Sonia
Dávila-Conn, Vanessa
Beristain-Barreda, Ángeles
Cárdenas-Sandoval, Miroslava
Becerril-Rodríguez, Manuel
Iracheta-Hernández, Patricia
Macías-González, Israel
García-Mendiola, Rebecca
Guzmán-Carmona, Alejandro
Zarza-Sánchez, Eduardo
Cruz, Raúl Adrián
González-Rodríguez, Andrea
Reyes-Terán, Gustavo
Ávila-Ríos, Santiago
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title_full HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title_fullStr HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title_full_unstemmed HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title_short HIV Pretreatment Drug Resistance Trends in Mexico City, 2017–2020
title_sort hiv pretreatment drug resistance trends in mexico city, 2017–2020
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708254/
https://www.ncbi.nlm.nih.gov/pubmed/34959542
http://dx.doi.org/10.3390/pathogens10121587
work_keys_str_mv AT garciamoralesclaudia hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT tapiatrejodaniela hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT matiasflorentinomargarita hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT quirozmoralesveronicasonia hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT davilaconnvanessa hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT beristainbarredaangeles hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT cardenassandovalmiroslava hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT becerrilrodriguezmanuel hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT irachetahernandezpatricia hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT maciasgonzalezisrael hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT garciamendiolarebecca hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT guzmancarmonaalejandro hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT zarzasanchezeduardo hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT cruzrauladrian hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT gonzalezrodriguezandrea hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT reyesterangustavo hivpretreatmentdrugresistancetrendsinmexicocity20172020
AT avilariossantiago hivpretreatmentdrugresistancetrendsinmexicocity20172020